DGAP-News: Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna's Omicron-Containing Bivalent Booster in the UK
Retrieved on:
Monday, August 15, 2022
Compte rendu, Science, Messenger RNA, Private Securities Litigation Reform Act, Security agency, GMT, SEC, Leadership, Clinical trial, Medication, Government, Degenerative disease, COVID-19, Company, Infection, Therapy, Vaccine, Biotechnology, Vaccine Taskforce (UK), Safety, RNA, Intention, MHRA, UK Health Security Agency, NHS, Severe acute respiratory syndrome coronavirus 2, ACCESS, RNA transfection, Health care, Omicron, EU
CAMBRIDGE, Mass.--(ACCESS WIRE)— AUGUST 15, 2022-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted conditional authorization for the use of the Omicron-containing bivalent COVID-19 booster vaccine, mRNA-1273.214 (Spikevax Bivalent Original/Omicron▼) as a booster dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. Spikevax Bivalent Original/Omicron is a next-generation bivalent vaccine that contains mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant of concern (BA.1).
Key Points:
- Spikevax Bivalent Original/Omicron is a next-generation bivalent vaccine that contains mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant of concern (BA.1).
- We are delighted with the MHRAs authorization of Spikevax Bivalent Original/Omicron, our next-generation COVID-19 vaccine.
- This bivalent vaccine has an important role to play in protecting people in the UK from COVID-19 as we enter the winter months.
- Moderna is working with The Vaccine Taskforce, UK Health Security Agency, and NHS to make
Spikevax Bivalent Original/Omicron available to the UK public.